Results 101 to 110 of about 20,750 (203)

Identification of BRAF V600E Mutation in Cerebrospinal Fluid Aids in Diagnosing Leptomeningeal Carcinomatosis Arising From Pleomorphic Xanthoastrocytoma: A Case Report

Cancer Reports, Volume 9, Issue 3, March 2026.
ABSTRACT Background Pleomorphic xanthoastrocytomas (PXAs) are rare primary central nervous system (CNS) tumors that appear heterogeneous on imaging and histology and typically cause headaches or seizures on initial presentation. Alongside high rates of favorable prognosis after surgical excision exist similarly high rates of recurrence.
Randy S. D'Amico, Patricia Avancena, Alon Kashanian, Rosivel Galvez, Deborah Gruber, Sami Saba, Avraham Zlochower, Manju Harshan, Morana Vojnic   +8 more
wiley   +1 more source

Treating malignant melanoma when a rare BRAF V600M mutation is present: case report and literature review

Romanian Journal of Internal Medicine, 2018
Recent years have brought major advances in the treatment of malignant melanoma. One such an advance is the treatment with BRAF tyrosine-kinase inhibitors in metastatic malignant melanomas that harbor mutations in the BRAF gene. The trials that have been
Popescu Andrei, Haidar Andrei, Anghel Rodica Maricela   +2 more
doaj   +1 more source

Expression of Drug Targets in Patients Treated with Sorafenib, Carboplatin and Paclitaxel [PDF]

, 2013
Introduction: Sorafenib, a multitarget kinase inhibitor, targets members of the mitogen-activated protein kinase (MAPK) pathway and VEGFR kinases.
A Hauschild, A Hauschild, A Sharma, A Yayon, AB Coleman, C Robert, Christopher R. Zito, DA Murphy, David L. Rimm, Fengmin Zhao, FS Hodi, GV Long, H Niessner, Harriet M. Kluger, HM Kluger, HT Arkenau, JM Mehnert, John M. Kirkwood, Katherine L. Nathanson, Keiran Smalley, Keith T. Flaherty, KT Flaherty, KT Flaherty, KT Flaherty, KT Flaherty, Kurt D'Andrea, L Adnane, L Jilaveanu, L Lang, L Liu, LB Jilaveanu, Lucia B. Jilaveanu, M Dolled-Filhart, M Karasarides, Melissa Wilson, MM McCarthy, MM McCarthy, MN Stein, PA Ott, PB Chapman, Q Wang, R Siegel, RA Scolyer, RL Camp, RL Camp, S Zhang, Sandra J. Lee, SM Wilhelm, T Eisen   +48 more
core   +3 more sources

Successful Management of Suspected Epstein–Barr Virus‐Associated Hemophagocytic Lymphohistiocytosis in BRAF‐Mutant Cholangiocarcinoma Following Treatment With Immune Checkpoint Inhibitors and BRAF/MEK Inhibitors: A Case Report

Cancer Reports, Volume 9, Issue 3, March 2026.
ABSTRACT Background The BRAF V600E mutation is a rare genetic alteration in cholangiocarcinoma for which sequential therapy with immune checkpoint inhibitors (ICIs) and BRAF/MEK inhibitors may be effective. However, the full spectrum of adverse events associated with the sequential use of these agents remains unclear. Hemophagocytic lymphohistiocytosis
Akira Shibata, Michihiro Ono, Shutaro Oiwa, Atsushi Uesugi, Seiya Saito, Makoto Usami, Tomoyuki Abe, Masahiro Yoshida, Masahiro Maeda, Kohichi Takada   +9 more
wiley   +1 more source

Differential influence of vemurafenib and dabrafenib on patients' lymphocytes despite similar clinical efficacy in melanoma [PDF]

, 2017
In this study, we demonstrate that vemurafenib but not dabrafenib reduces peripheral lymphocyte counts in melanoma patients while both agents show similar clinical efficacy. Within the lymphocyte compartment, vemurafenib selectively decreases circulating
Al Ghazal, P., Berking, C., Goldinger, S. M., Griewank, K. G., Gutzmer, R., Hassel, J., Hillen, U., Kähler, K. C., Livingstone, E., Loquai, C., Paschen, A., Schadendorf, D., Schilling, B., Sondermann, W., Sucker, A., Trefzer, U., Utikal, J., Weide, B., Wilhelm, T., Zelba, H., Zhao, F., Zimmer, L.   +21 more
core  

Extent and Incidence of Pseudo‐Worsening of Kidney Function Due to Oral Antitumor Therapeutics in the AMBORA Cohort: An Analysis of Real‐World Data

Clinical Pharmacology &Therapeutics, Volume 119, Issue 3, Page 802-811, March 2026.
A considerable number of oral antitumor therapeutics (OAT) has the potential for causing pseudo‐worsening of kidney function (PW) due to inhibition of renal creatinine secretion, i.e., kidney function is unaffected, while creatinine‐based calculation of glomerular filtration rate (eGFR) erroneously indicates an impaired kidney function.
Michael I. Sponfeldner, Pauline Dürr, Phyllis Lensker, Katja Gessner, Lisa Cuba, Rainer Fietkau, Markus F. Neurath, Bernd Wullich, Marianne Pavel, Carola Berking, Matthias W. Beckmann, Andreas Mackensen, Frank Dörje, Martin F. Fromm   +13 more
wiley   +1 more source

Phase I dose-escalation trial of the oral AKT inhibitor uprosertib in combination with the oral MEK1/MEK2 inhibitor trametinib in patients with solid tumors. [PDF]

, 2020
PurposeThis study aimed to determine the safety, tolerability, and recommended phase II doses of trametinib plus uprosertib (GSK2141795) in patients with solid tumors likely to be sensitive to MEK and/or AKT inhibition.MethodsThis was a phase I, open ...
Becerra, Carlos, D'Amelio, Anthony M, Ellis, Catherine, Gauvin, Jennifer, Gonzalez, Rene, Heist, Rebecca S, Ibrahim, Nageatte, Kalyana-Sundaram, Shanker, Kleha, Joseph F, Kurzrock, Razelle, Leonowens, Cathrine, Means-Powell, Julie, Tan, Antoinette R, Tolcher, Anthony W, Valero, Vincente, Wang, Chenxi, Werner, Theresa L, Yan, Li   +17 more
core  

Anorectal Melanoma [PDF]

, 2018
Anorectal melanoma (AM) is a rare malignancy, characterized by aggressive behavior and a poor prognosis. AM is more frequent in female patients aged over 50 years.
Dario Didona, Giovanni Paolino, Giulia Macrì, Santo Raffaele Mercuri., Stefano Calvieri   +4 more
core   +1 more source

Multi‐omic profiling defines three distinct molecular subtypes of urothelial carcinoma with implications for precision therapy

Clinical and Translational Medicine, Volume 16, Issue 3, March 2026.
We developed three UC clusters, applicable for MIBC and NMIBC, which were validated using transcriptomic- and proteomic datasets. Publically available UC cell lines were assigned to the clusters, to have in vitro models representing each cluster. The clusters differ in molecular and biological signatures, with distinct prognostic and therapeutic ...
Nils C. H. van Creij, Piotr Tymoszuk, Florian Handle, Andreas Seeber, Teresa Sellemond, Agnieszka Martowicz, Eva Comperat, Hamed Wafa, Steffen Ormanns, Michael Günther, Walther Parson, Maxim Noeparast, Frédéric R. Santer, José Daniel Subiela, Petros Grivas, Roger Li, Zoran Culig, Renate Pichler   +17 more
wiley   +1 more source

Cost-effectiveness analysis of pembrolizumab versus targeted therapies in advanced melanoma

Качественная клиническая практика, 2018
Background. The modern therapies of advanced melanoma include targeted medicines for patients with BRAF mutations. Nowadays, a new perspective on immuno-oncologic medicine pembolizumab became available in Russia. Objective. Assessment of the clinical and
E. G. Kosolapov, F. S. Kochenkov, S. K. Zyryanov, O. A. Gladkov   +3 more
doaj